Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Karyopharm Therapeutics Inc. has received a consensus recommendation of "Moderate Buy" from five research firms, with an average 1-year price target of $34.00.
• Recent brokerage ratings have seen a mix of downgrades and changes, with Robert W. Baird lowering their price target from $42.00 to $25.00 and HC Wainwright changing their rating from "buy" to "neutral".
• Institutional investors hold 66.44% of Karyopharm's shares, with Adage Capital Partners increasing their stake by 46.3% in the fourth quarter.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $34.00.

A number of brokerages have recently weighed in on KPTI. Barclays raised their price objective on shares of Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. Wall Street Zen cut shares of Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. Robert W. Baird dropped their price objective on shares of Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, August 12th. Royal Bank Of Canada dropped their price objective on shares of Karyopharm Therapeutics from $34.00 to $33.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Finally, HC Wainwright cut shares of Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, July 16th.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock traded up $1.15 during midday trading on Thursday, reaching $7.46. 177,722 shares of the company traded hands, compared to its average volume of 205,197. The firm's 50 day simple moving average is $4.63 and its two-hundred day simple moving average is $5.43. Karyopharm Therapeutics has a 1-year low of $3.51 and a 1-year high of $16.95. The firm has a market cap of $64.68 million, a PE ratio of -0.51 and a beta of 0.28.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million for the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently made changes to their positions in the stock. Baird Financial Group Inc. purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $45,000. XTX Topco Ltd acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at $56,000. Bridgeway Capital Management LLC acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at $163,000. Velan Capital Investment Management LP acquired a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at $27,000. Finally, Focus Partners Wealth acquired a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at $31,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).